Introduction Anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC) represents 3-5% of NSCLC cases and is often associated with younger, non-smoking patients (1). While ALK tyrosine kinase inhibitors (TKIs) have improved outcomes, challenges such as brain metastases and acquired resistance persist (1). Lorlatinib is a third-ge
Case of Pulmonary Embolism with Syncope
544 Reached4 Likes
Black Lesion in Old Female
1972 Reached5 Comments11 Likes
Case of Increased Risk of Pregnancy-associated Breast Cancer Recurrence
1007 Reached2 Comments
Treatment of Recurrent Adult Medulloblastoma
2602 Reached1 Comments4 Likes
Management of Metastatic Prostate Cancer
1037 Reached5 Comments2 Likes